Can UroLift be safely performed in men with prostate cancer before radiotherapy?

Background To evaluate the feasibility, safety, and early outcomes of UroLift as a strategy to optimise bladder outlet obstruction prior to prostate radiotherapy in men with prostate cancer. Methods We conducted a multicentre pilot feasibility study of consecutive men undergoing UroLift before planned prostate radiotherapy across three UK centres. The cohort comprised prospectively enrolled participants from the COSTAR feasibility trial (NCT05840549) and a contemporaneous off-trial pilot cohort managed according to the same eligibility criteria and clinical pathway; data were collected prospectively in both cohorts. Outcomes included perioperative safety, catheterisation, patient-reported improvement (PGI-I), and radiotherapy completion. Results Twenty-one men underwent UroLift pre radiotherapy (median age 74.8 years; median prostate volume 43 cc). Baseline median IPSS was 20. Two-thirds had ≥T3 prostate cancer, and 48% were NCCN very high risk. Median number of implants was 4. Adjunct procedures were required in 19%. All procedures were day case, with median operative time of 14 min. Postoperative catheterisation occurred in 33%, with all patients successfully completing trial without catheter. One Clavien–Dindo grade IIIa complication occurred. At six weeks, PGI-I responses were available for 12 COSTAR participants, of whom 10 (83%) reported feeling ‘much better’ or ‘very much better. All patients completed radiotherapy. Conclusions In this small multicentre pilot study, UroLift prior to prostate radiotherapy was feasible as a day-case procedure, with short operative times, low observed perioperative morbidity and successful catheter removal in all patients requiring temporary postoperative catheterisation. These findings support the procedural feasibility of UroLift as a pre-radiotherapy bladder outlet intervention in appropriately selected men with prostate cancer and provide a basis for further prospective comparative evaluation. Trial registration Clinical Trials.gov ID NCT05840549 2023-01-17.

Authors

Publication Details

Journal
BMC Urology
Published
2026-11-20
DOI
https://doi.org/10.1186/s12894-026-02468-9
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Can UroLift be safely performed in men with prostate cancer before radiotherapy?

Mieke Van Hemelrijck, Kathie Alexina Wong, David M. Nicol, John Withington et al.
BMC Urology
Prostate Cancer Diagnosis and Treatment
article

Can UroLift be safely performed in men with prostate cancer before radiotherapy?

Mieke Van Hemelrijck, Kathie Alexina Wong, David M. Nicol, John Withington, Simone Giona, Charlotte Moss, Netty Kinsella, Vincent S Khoo, Jai H. Seth, Declan J. Cahill, Toby Page, Chris Cottrell, Holly Townsend-Renn, Beth Russell, Ananda Dhansekaran, Luke Mahoney, Nicholas James
article en

Abstract

Background To evaluate the feasibility, safety, and early outcomes of UroLift as a strategy to optimise bladder outlet obstruction prior to prostate radiotherapy in men with prostate cancer. Methods We conducted a multicentre pilot feasibility study of consecutive men undergoing UroLift before planned prostate radiotherapy across three UK centres. The cohort comprised prospectively enrolled participants from the COSTAR feasibility trial (NCT05840549) and a contemporaneous off-trial pilot cohort managed according to the same eligibility criteria and clinical pathway; data were collected prospectively in both cohorts. Outcomes included perioperative safety, catheterisation, patient-reported improvement (PGI-I), and radiotherapy completion. Results Twenty-one men underwent UroLift pre radiotherapy (median age 74.8 years; median prostate volume 43 cc). Baseline median IPSS was 20. Two-thirds had ≥T3 prostate cancer, and 48% were NCCN very high risk. Median number of implants was 4. Adjunct procedures were required in 19%. All procedures were day case, with median operative time of 14 min. Postoperative catheterisation occurred in 33%, with all patients successfully completing trial without catheter. One Clavien–Dindo grade IIIa complication occurred. At six weeks, PGI-I responses were available for 12 COSTAR participants, of whom 10 (83%) reported feeling ‘much better’ or ‘very much better. All patients completed radiotherapy. Conclusions In this small multicentre pilot study, UroLift prior to prostate radiotherapy was feasible as a day-case procedure, with short operative times, low observed perioperative morbidity and successful catheter removal in all patients requiring temporary postoperative catheterisation. These findings support the procedural feasibility of UroLift as a pre-radiotherapy bladder outlet intervention in appropriately selected men with prostate cancer and provide a basis for further prospective comparative evaluation. Trial registration Clinical Trials.gov ID NCT05840549 2023-01-17.

BMC Urology
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon